GH Research vs Rein Therapeutics
GHRS and RNTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GHRS and RNTX compare
Rein Therapeutics scores higher on the StockData Score (6 against 1 for GH Research), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GHRS | RNTX |
|---|---|---|
| Size and price | ||
| Market cap | – | $30.7M |
| Share price | $18.27 | $0.356 |
| Change, 1 year | 30.5% | −71.5% |
| Change, 5 years | −17.7% | −97.3% |
| Beta (5Y) | 1.80 | 2.30 |
| Employees | 73 | 10 |
| StockData Score | ||
| Total score | 1 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 0.6× |
| Profitability | ||
| Return on equity | – | −96.4% |
| Return on invested capital | – | −145% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −257.1× | – |
| Current ratio | 28.70 (better) | 4.27 |
| Altman Z-score | – | −8.96 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | −179% |
| Shareholder yield | – | −179% |
| Ownership | ||
| Held by institutions | 83.0% | 47.3% |
| Held by insiders | 45.6% | 9.6% |
| Insider net buying, 12 months | – | $74.7K |
| Short interest, % of float | 6.2% | 0.91% |
Go deeper
- GHRS stock overview
- GHRS income statement
- GHRS valuation and score
- RNTX stock overview
- RNTX income statement
- RNTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.